<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093727</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-LAN-2013-39</org_study_id>
    <nct_id>NCT03093727</nct_id>
  </id_info>
  <brief_title>Characterization of Pulmonary Langerhans Cell Histiocytosis</brief_title>
  <official_title>Functional and Genetical Characterization of Pulmonary Langerhans Cell Histiocytosis: Diagnostic and Therapeutical Implications.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Very recent studies indicate that a high percentage of HCL, about 50%, have mutations in the&#xD;
      B-RAF oncogene. The development of ultrasensitive methodologies capable of identifying these&#xD;
      mutations in bronchoalveolar lavage will represent a significant advance in the diagnosis and&#xD;
      treatment of these patients. An undetermined percentage of HCL does not present mutations in&#xD;
      B-RAF. Consequently, the deep genetic analysis, through the use of techniques of massive&#xD;
      sequencing, can favor the identification of new alterations that contribute to the&#xD;
      development of the disease.&#xD;
&#xD;
      We hypothesized that patients with HCL may present a different inflammatory state to healthy&#xD;
      subjects or smokers, allowing us to identify new biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to expand the genetic and pathophysiological knowledge of&#xD;
      this disease. For this, the following points will be developed:&#xD;
&#xD;
        -  Identification of mutations in the B-RAF oncogene in Spanish patients with pulmonary&#xD;
           LCHF.&#xD;
&#xD;
        -  Development of ultrasensitive genetic analysis methods capable of identifying mutations&#xD;
           in B-RAF in bronchoalveolar lavage (BAL) samples.&#xD;
&#xD;
        -  To determine if patients with mutations in the B-RAF oncogene present distinct clinical,&#xD;
           radiological and / or functional characteristics compared to those with absence of the&#xD;
           mutation.&#xD;
&#xD;
        -  Characterization of the inflammatory profile of patients with HPCL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2013</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Number of participants with mutations in the B-RAF oncogene in Langerhans histiocytosis</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Langerhans Cell Histiocytoses</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Langerhans cell histiocytosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Men and women with no age limitation&#xD;
&#xD;
          -  Established histiological diagnosis of histiocytosis of langerhans cells.&#xD;
&#xD;
          -  HCLP-compatible clinical-radiological picture.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Non-acceptance of informed consent.&#xD;
&#xD;
          -  Absence in clinical history of clinical, radiological and functional variables&#xD;
             essential for the diagnosis of HLCP.&#xD;
&#xD;
          -  Psychiatric disorder or limitation for study compression (including language,&#xD;
             socio-cultural problem, etc.).&#xD;
&#xD;
          -  Radiological findings suggestive of another chronic lung disease.&#xD;
&#xD;
          -  Active respiratory infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Erika Delgado Espinoza</last_name>
      <email>CDelgadoE@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Diego Castillo, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2017</study_first_posted>
  <last_update_submitted>August 16, 2020</last_update_submitted>
  <last_update_submitted_qc>August 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
    <mesh_term>Histiocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

